

Authors

Prof. György ÁBRAHÁM, MD, PhD, DMSc

University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine

Prof. Zsuzsanna ARÁNYI, MD, DSc

Semmelweis University, Faculty of Medicine
Department of Neurology

Péter BACSUR, MD

clinical physician
University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine,
Gastroenterology Centre

Prof. László BARKAI, MD, DSc

Pavol Jozef Šafárik University in Košice,
Faculty of Medicine
Children's University Hospital in Košice
Óbuda University Research and Innovation
Center (EKIK),
Physiological Controls Research Center

Magdolna BÉKEFFY, MD

senior resident
Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Prof. László CZAKÓ, MD

University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine,
Gastroenterology Centre

† Prof. Judit DARÓCZY, MD, DSc

Prof. Judit DEMETER, MD, PhD, DSc

professor emerita
Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Prof. Triantafyllos DIDANGELOS, MD, PhD

„AHEPA” Hospital, Aristotle University of
Thessaloniki Medical School
First Propedeutic Department of Internal
Medicine, Diabetes Centre

Virág ENDRÉDI, MD

senior resident
Szent Ferenc Hospital in Budapest

Imola FEJES, MD

assistant lecturer
University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine,
Nephrology-Hypertonia Centre

Viktória FERENCZ, MD, PhD

assistant professor
Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Prof. László GERŐ, MD, PhD, DSc

professor emeritus
Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Prof. Mariann HARANGI, MD

University of Debrecen, Faculty of Medicine
Department of Internal Medicine
Division of Metabolism

Zsolt HERMÁNYI, MD, MSc*chief medical director*

Bajcsy-Zsilinszky Hospital, Budapest
Central Outpatient Department

Viktor HORVÁTH, MD, PhD*assistant professor*

Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Ildikó ISTENES, MD, PhD*assitant professor*

Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

György JERMENDY, MD, DSc

Bajcsy-Zsilinszky Hospital, Budapest
Third Department of Internal Medicine

Éva KÁDÁR, MD*psychiatrist*

Mária Medical Private Practice

Prof. Péter KEMPLER, MD, DSc

Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Zsuzsanna KERÉNYI, MD, PhD*medical director*

Trantor '99 Bt. Metabolism Center

Katalin KERESZTES, MD, PhD*chief physician*

Gottsegen National Cardiovascular Center
Department of Cardiology

Gábor KISS, MD*neurologist, neuropsychologist*

Újpesti Egészségügyi Nonprofit Kft.

Prof. Márk KOLLAI, MD, DSc

Semmelweis University, Faculty of Medicine
Institute of Human Physiology and Clinical
Experimental Research

Prof. Sámuel KOMOLY, MD, DSc*professor emeritus*

University of Pécs Medical School
Department of Neurology

Anna Erzsébet KÖREI, MD, PhD*assistant professor*

Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

habil. Péter LÉGRÁDY, MD, PhD*associate professor*

University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine,
Nephrology-Hypertonia Centre

Sándor MAGONY, MD*chief clinical physician*

University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine

Prof. Rayaz A. MALIK, MBChB, PhD, FRCP

Weill Cornell Medicine-Qatar, Doha

Prof. Gergő Attila MOLNÁR, MD*deputy director*

University of Pécs Medical School
Second Department of Internal Medicine,
Nephrology-Diabetology Center

Prof. Tamás MOLNÁR, MD

University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine,
Gastroenterology Centre

Szabolcs NYIRATY, MD, PhD

assistant professor

University of Szeged, Albert Szent-Györgyi

Clinical Centre

Department of Internal Medicine

Prof. Nikolaos PAPANAS, MD, PhD

Head of Diabetes Centre-Diabetic Foot

Clinic

Democritus University of Thrace,

Alexandroupolis

Second Department of Internal Medicine

† Prof. Gábor POGÁTSÁ, MD, DSc

professor emeritus

Fővárosi Önkormányzat Szent János Kórház

II. Belosztály, Diabetológiai Szakrendelés

III. Belosztály, Kardiológiai Szakrendelés

Ioannis N. PETROPOULOS, BSc, MSc, PhD

assistant professor of Research in Medicine

Weill Cornell Medicine-Qatar, Doha

Zsuzsanna PUTZ, MD, PhD

associate professor

Semmelweis University, Faculty of Medicine

Department of Internal Medicine and

Oncology

László ROSTA, MD

chief clinician

General Medical Practica Felsőrajk

András ROSZTÓCZY, MD, PhD

associate professor

University of Szeged, Albert Szent-Györgyi

Clinical Centre

Department of Internal Medicine,

Gastroenterology Centre

Eszter SÉLLEY, MD

assistant lecturer

University of Pécs Medical School

Second Department of Internal Medicine,

Nephrology-Diabetology Center

Dinesh SELVARAJAH, MBChB, MPH, PhD, MRCP

University of Sheffield Medical School

Division of Clinical Medicine

Gábor SIMONYI, MD, PhD

associate professor, head of centre and department

Szent Imre University Teaching Hospital,

South Buda Central Hospital

Metabolism Centre

University of Pécs Clinical Centre

Department of Obesityology

Vincenza SPALLONE, MD, PhD

associate professor Turris Virgatae

Tor Vergata University of Rome

Department of Systems Medicine

Ovidiu Alin STIRBAN, MD

head of Diabetes Department

Asklepios Klinik, Birkenwerder

Erzsébet Szabóné RÉVÉSZ, MD

chief clinician

Fejér County Szent György University

Teaching Hospital

Department of General Surgery

Prof. Ferenc SZALAY, MD, DSc

professor emeritus

Semmelweis University, Faculty of Medicine

Department of Internal Medicine and

Oncology

Ferenc SZTANEK, MD

University of Debrecen, Faculty of Medicine

Department of Internal Medicine

Division of Metabolism

Prof. István TAKÁCS, MD DSc

head of department

Semmelweis University, Faculty of Medicine

Department of Internal Medicine and

Oncology

† Prof. Gyula TAMÁS, MD

Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Prof. Solomon TESFAYE, MB, ChB, MD, FRCP

Sheffield Teaching Hospitals and the
University of Sheffield
Department of Diabetes

Prof. András TISLÉR, MD, PhD

chief clinician
Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Csaba Zsigmond TÓTH, MD

chief clinician
University of Debrecen, Faculty of Medicine
Department of Surgery

Orsolya Erzsébet VÁGI, MD

assistant lecturer
Semmelweis University, Faculty of Medicine
Department of Internal Medicine and
Oncology

Prof. Tamás VÁRKONYI, MD, PhD

University of Szeged, Albert Szent-Györgyi
Clinical Centre
Department of Internal Medicine

Prof. Gábor WINKLER, MD, DSc

deputy director
Szent János Centre Hospital of North Buda

Prof. István WITTMANN, MD, DSc

head of department
University of Pécs Medical School
Second Department of Internal Medicine,
Nephrology-Diabetology Center

Prof. Dan ZIEGLER, MD, DHC, FRCPE

German Diabetes Center
Institute for Clinical Diabetology,
Heinrich Heine University Düsseldorf
Leibniz Center for Diabetes Research

Dear Reader,

It has been more than a quarter of a century since Professor Péter Kempler published the first Hungarian summary of the pathophysiology and the diagnostic and therapeutic possibilities of neuropathies. Over the past 25 years, there have been tremendous advances in our knowledge about neuropathies, but unfortunately, in many ways, this has not been matched by changes in clinical practice. A significant portion of patients are not even diagnosed, and the treatment they receive is not in line with current guidelines. This is why this summary is so important, as it can help clinicians both in making a diagnosis and in initiating state-of-the-art therapies.

The book is also a reminder that neuropathy is a truly multidisciplinary disease. Although the medical community considers diabetes to be its main cause, there are many other common diseases that may also be responsible. To name just the most prominent, alcoholic and non-alcoholic liver disease, chronic renal failure, hypertension, various nutritional deficiencies, and metabolic disorders can lead to peripheral nerve damage. This goes to show that there is almost no field of medicine that does not have to deal with the issue of neuropathy. A thorough knowledge of the disease is also extremely important because the typical clinical symptoms—described in detail in this monograph—can be recognised by simple examinations, which means a diagnosis can be made even in the GP's office and, on the basis of this knowledge, effective treatment can be started. Early diagnosis is also a prerequisite for preventing serious complications in neuropathies. Compared to the previous three monographs, perhaps the greatest novelty of this work is the presentation of data from Hungary based on domestic studies and an evidence-based approach to the management of neuropathy based on large-scale clinical trials. Clinical trials have now shown that the combined administration of conventional treatment options (benfotiamine, alpha-lipoic acid) in appropriate doses, supplemented by symptomatic treatment, can effectively improve clinical symptoms and the risk of long-term complications in advanced neuropathies.

I am particularly pleased that the most prominent members of the profession, including current and former colleagues of the Department of Internal Medicine and Oncology (formerly known as the 1st Department of Internal Medicine), have made significant contributions to the production of this excellent monograph—this is no coincidence, as a significant number of Hungarian neuropathology specialists started their careers in the working group led by Professor Péter Kempler.

I am confident that fellow medical experts who read this book will be able to use the latest theoretical knowledge to diagnose and effectively treat neuropathies in their daily practice. The importance of this step cannot be overstated in the case of such a substantial, under-diagnosed and now well-treatable disease.

I highly recommend this book to all interested experts, and I wish you success in applying the knowledge gained in your daily work.

Budapest, 10 December 2024

Dr István Takács
Professor of Medicine

Introduction

What you hold in your hands is the fourth manual on neuropathies. The first book was published in 1996, the second in 2002, and the third in 2011. The longest period between two publications was before this, the current edition, and I pondered for a long time whether I should even bother. Similarly to this edition, all three previous editions were also published in English and the third in Russian as well, just as the fourth edition will be published in both languages.

When we started our neuropathy studies at the 1st Department of Internal Medicine at Semmelweis University, this complication was considered an interesting but rare disease; it was thought not to occur in type 2 diabetics. In 1981, 44 years ago, my boss at the time, András Váradi, gave me a short Lancet article on cardiovascular autonomic neuropathy in diabetic patients. It was written by David Ewing — it is based on his description that we still refer to tests for autonomic neuropathy as Ewing tests. András told me that although I was still young, I had to do some scientific work, for which I would need only an ECG and a blood pressure monitor. This would allow me to examine 10-12 patients if I was lucky and then possibly even give a lecture on the subject. To this day, I am very grateful to András. Unfortunately, he is no longer with us due to an unfortunate accident.

Carrying out cardiovascular reflex tests is a simple but time-consuming task and, as a young trainee, I didn't have the opportunity during my day-to-day work. At the same time, I was well aware of the potential of research within the framework of the medical students' scientific association (TDK). By then, the Department was headed by Professor Holló, who agreed to take on four TDK students, although he noted that he was not aware that I had done any scientific work. I was very lucky to have these four bright, hardworking third-year students who did an excellent job for four years. I would like to highlight the work done by Anna Mosonyi and Andrea Tumpek. Based on the positive initial experience, 88 TDK students are still working in the working group today. Ten of them have been admitted to the faculty and five of them have defended their doctoral theses.

Work on neuropathy typically either addresses the neurological damage caused by diabetes or follows a neurological line of thought. The authors of this book are predominantly internists, though distinguished experts in neurology, paediatrics, and psychiatry have also participated in writing this book. At the same time, we have tried to address the main concerns of general practitioners, internists, and diabetologists in particular. A separate chapter covers aspects of paediatric diabetes and the characteristics of neuropathy associated with pre-diabetes. In addition to diabetes, the characteristics of neuropathy associated to chronic liver disease, chronic kidney disease, and haematological diseases are described in detail. Compared to the third edition, a new chapter has been added, including several new diagnostic methods, sections on polycystic ovary syndrome and thyroid disorders, and sections on critical illness neuropathy, depression, and neuropathy.

Several new diagnostic techniques not included in previous editions are presented, including ultrasound examination of the nerves, punch skin biopsy, and corneal confocal microscopy.

The presentation of the risk factors for neuropathy and the different treatment options for neuropathy is now more comprehensive. Within the former, the importance of vitamin D should be highlighted.

The list of authors has expanded along with the content. In total, 56 authors have contributed to the fourth edition. I am grateful for the help of those who contributed to the writing of the first edition, many of whom have become prominent authorities and professors in the field over the decades. I was very happy that the staff of the 2nd Department of Internal Medicine and Centre for Nephrology and Diabetology of the Clinical Centre of the University of Pécs, the Department of Medicine of the University of Szeged, and the School of Internal Medicine of the University of Debrecen also participated in the preparation of the fourth edition, and I would like to thank them all for their work. I am particularly honoured that many staff members from my workplace, the Department of Internal Medicine and Oncology of Semmelweis University (formerly known as the 1st Department of Internal Medicine), have contributed to the writing of the book chapters; some of them my own staff members, some of them members of other working groups.

The first three editions of the neuropathy handbook were authored entirely by Hungarians. For the fourth edition, the authorship has been internationalised, with leading international authorities on neuropathic diabetics who have been working on neuropathy for decades, each contributing a new chapter, and several of them chairing the Neuropathy Working Group of the European Diabetes Association (NEURODIAB).

I would also like to thank my wife, Dr Éva Kádár, for her help in so many ways, and Dr Tamás Várkonyi for his work as co-editor.

Dr Péter Kempler

Contents

Authors	5
Foreword	9
Introduction	11
Abbreviations	13

1. The aetiology of neuropathies 29

Péter Kempler, Katalin Keresztes, Sámuel Komoly, Gábor Simonyi

1.1. Neurological disorders	29
1.2. Internal medicine diseases	30
1.2.1. Other metabolic diseases	31
1.2.2. Organic heart diseases	31
1.3. Other pathological factors	37

2. Pathomorphology and pathomechanism 45

Sámuel Komoly, Gábor Winkler

2.1. Pathomorphology of nerve damage	45
2.1.1. Structure and function of the peripheral nerve	45
2.1.2. Types of peripheral nerve damage	47
2.2. The pathophysiology of neuropathies	48
2.2.1. Pathophysiology of diabetic neuropathy	49

3. Types, clinical picture, diagnosis, and prognosis of somatic neuropathy 61

Zsuzsanna Arányi, Triantafyllos Didangelos, Zsolt Hermányi, Viktor Horváth, Éva Kádár, Péter Kempler, Gábor Kiss, Sámuel Komoly, Anna Körei, Rayaz A. Malik, Ioannis N. Petropoulos, Zsuzsanna Putz, László Rosta, Ovidiu Alin Stirban, Orsolya Erzsébet Vági, Tamás Várkonyi

3.1. Types and clinical features of somatic neuropathy	61
3.1.1. Pain and polyneuropathy	62
3.1.2. Mononeuropathies	65
3.1.3. Radiculopathies	66
3.2. Clinical presentation of somatic neuropathy in diabetes mellitus	67
3.2.1. Small fibre neuropathy	72
3.2.2. Prognosis of somatic neuropathy in diabetes mellitus	74
3.3. Diagnosis of somatic neuropathy	80
3.3.1. When to see a neurologist?	82
3.3.2. Neuropathy Centre Network—from alpha to omega	82
3.3.3. Electrophysiological test methods	83
3.3.4. Ultrasound examination of the peripheral nerves	87

3.3.5. Calibrated tuning fork	94
3.3.6. Other methods for measuring vibration perception	95
3.3.7. Monofilament	96
3.3.8. Neurometer	96
3.3.9. Computer Aided Sensory Evaluator, Version four (CASE IV)	100
3.3.10. Medoc system	101
3.3.11. Sudoscan	102
3.3.12. Measurement of skin autofluorescence: relevance for diabetic neuropathy	103
3.3.13. Punch skin biopsy	106
3.3.14. Corneal Confocal Microscopy for Diabetic Neuropathy and Beyond	107
3.3.15. Toronto Expert Group recommendation	112

4. Clinical presentation and diagnosis of cardiovascular autonomic neuropathy

125

Ildikó Istenes, György Jermendy, Katalin Keresztes, Márk Kollai, Anna Körei, László Rosta, András Tislér

4.1. Clinical signs of cardiovascular autonomic neuropathy	125
4.1.1. Resting tachycardia	125
4.1.2. Orthostatic hypotension	129
4.1.3. Asymptomatic myocardial ischaemia/infarction	131
4.1.4. Arrhythmias	134
4.1.5. Circulatory and respiratory arrest	140
4.1.6. Abnormal left ventricular function	141
4.1.7. Hypertension due to autonomic neuropathy	143
4.1.8. Autonomic neuropathy and sudden death	144
4.2. Changing the physiological circadian rhythm of heart rate and blood pressure	147
4.2.1. Factors affecting the variability of blood pressure	147
4.2.2. The circadian rhythm of blood pressure	148
4.2.3. Regulation of the circadian rhythm	149
4.3. Diagnostics of cardiovascular autonomic neuropathy	150
4.3.1. Cardiovascular reflex tests (the Ewing battery of five standard tests)	151
4.3.2. Other cardiovascular reflex tests	156
4.3.3. Efforts to simplify diagnostics	156
4.3.4. Computer analysis of cardiovascular reflex tests	157
4.3.5. Measuring the corrected QT interval	158
4.3.6. Heart rate variability	160
4.3.7. Determination of arterial baroreflex sensitivity	162
4.3.8. Scintigraphic analysis of cardiac adrenergic neurons	164
4.4. Prognosis of cardiovascular autonomic neuropathy	164

5. Clinical presentation, diagnosis, and treatment of gastrointestinal autonomic neuropathy

185

Péter Bacsur, László Czakó, Viktor Horváth, Tamás Molnár, András Rosztóczy, Tamás Várkonyi

5.1. The involvement of different levels of gastrointestinal neuroregulation in diabetes	185
---	------------

5.2. Manifestations specific to each organ (clinical presentation, treatment)	188
5.2.1. Oesophagus	188
5.2.2. Stomach	190
5.2.3. Small and large intestines, rectum	193
5.2.4. Motility disorders of the gallbladder—increased incidence of cholelithiasis	195
5.2.5. Pancreas	197

6. Other clinical manifestations of autonomic neuropathy	205
---	------------

Viktória Ferencz, Ildikó Istenes, György Jermendy, Péter Kempler, Zsuzsanna Kerényi, Anna Körei, Gyula Tamás (✉), Tamás Várkonyi, Nikolaos Papanas

6.1. Urogenital autonomic neuropathy	205
6.1.1. Urinary retention	205
6.1.2. Erectile dysfunction	206
6.2. Impairment of sudomotor function	216
6.2.1. The indicator test for sudomotor function Neuropad: an update on its role in diabetic neuropathy	216
6.3. Disorders of pupil function	223
6.4. The relationship between neuropathy and osteoporosis	223
6.5. Haemodynamic consequences of arterial vasodilatation and increased arteriovenous shunting	227
6.5.1. Diabetic osteo-neuroarthropathy	227
6.5.2. Neuropathic oedema	232
6.5.3. Mönckeberg sclerosis	232
6.6. Metabolic effects of autonomic neuropathy	233
6.6.1. The relationship between autonomic neuropathy and catecholamine metabolism	233
6.6.2. Pathomechanism of hypoadrenergic and hyperadrenergic orthostatic hypotension	235
6.6.3. Changes in renin metabolism	235
6.6.4. Associations between autonomic neuropathy and hypoglycaemia	236
6.6.5. Impaired autonomic function due to hypoglycaemia: a specific form of autonomic neuropathy?	237

7. The effect of carbohydrate metabolism status on the development and progression of neuropathy	255
---	------------

György Jermendy, Zsuzsanna Kerényi, Szabolcs Nyiraty, Gyula Tamás (✉), Tamás Várkonyi

7.1. The role of normoglycaemia	255
7.1.1. The role of glucose variability	256
7.2. Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications Trial (EDIC)	259
7.2.1. Diabetes Control and Complications Trial (DCCT)	259
7.2.2. Epidemiology of Diabetes Interventions and Complications trial (EDIC)	261
7.2.3. Trends in the incidence of neuropathic complications during DCCT	263
7.2.4. Trends in the incidence of neuropathic complications during EDIC	264
7.2.5. Implications of DCCT/EDIC – considering the need for intensive conservative insulin therapy in type 2 diabetes mellitus	266

7.3. United Kingdom Prospective Diabetes Study (UKPDS)	267
7.3.1. The metformin arm of the UKPDS	272
7.3.2. Follow-up of the UKPDS	273
7.3.3. The relationship between autonomic neuropathy and glucose variability in diabetes mellitus	275

8. Other risk factors of neuropathy and its prevalence in diabetes mellitus

281

László Gerő, Mariann Harangi, Péter Kempler, Katalin Keresztes, Zsuzsanna Kerényi, Anna Körei, Zsuzsanna Putz, Ferenc Sztanek, Gyula Tamás (†), Dan Ziegler

8.1. Factors affecting prevalence data	281
8.2. Risk factors of diabetic neuropathy	281
8.2.1. Age, duration of diabetes	285
8.2.2. Obesity	285
8.2.3. Associations between diabetic neuropathy and lipid metabolism	291
8.2.4. Vitamin D deficiency and neuropathy	296
8.2.5. Xanthine oxidase activity and diabetic neuropathy	299
8.2.6. Hyperhomocysteinemia	300
8.2.7. Vitamin B ₆ deficiency	305
8.2.8. Vitamin B ₁₂ deficiency	305
8.2.9. Folic acid deficiency	307
8.2.10. Smoking	307
8.3. Brief literature review on the prevalence of diabetic neuropathy	309
8.4. Prevalence of diabetic neuropathy in Hungary	310
8.5. The EURODIAB IDDM Complications Study	312
8.5.1. Pooled results of the EURODIAB IDDM Complications Study	312
8.5.2. Hungarian results of the EURODIAB IDDM Complications Study	312
8.6. EURODIAB Prospective Complications Study	315
8.7. PROTECT Study	316
8.7.1. Introduction	316
8.7.2. Aims	317
8.7.3. Setting	317
8.7.4. Results	320
8.7.5. Discussion	327
8.7.6. Cross-sectional study	327
8.7.7. Follow-up study	330
8.7.8. Study limitations	331
8.7.9. Conclusions	331
8.8. Diabetic neuropathy in pregnancy complicated by diabetes	332
8.9. Neuropathy due to diabetes and other concurrent pathological factors	337

9. Neuropathy in prediabetes

351

Zsuzsanna Putz

10. Neuropathy in other endocrine diseases

355

Virág Endrédy, Zsolt Hermányi, Péter Kempler, Sándor Magony, Tamás Várkonyi

10.1. Features of neuropathy in polycystic ovary syndrome 355

10.2. Neuropathy in thyroid diseases 357

10.2.1. Introduction 357

10.2.2. Literary history 357

10.2.3. Our own studies 358

10.2.4 Discussion 362

11. The genetic aspects of diabetic neuropathy

365

Zsuzsanna Putz, Vincenza Spallone

11.1. The potential role of transketolase polymorphism in the therapy of diabetic neuropathy 365

12. Neuropathy in childhood diabetes

379

László Barkai

12.1. Prevalence 379

12.2. Risk factors in childhood 380

12.3. Clinical manifestations in childhood 381

12.4. Testing methods, screening 382

12.5. Preventive and therapeutic options 383

12.5.1. Experience with the benfotiamine treatment of peripheral sensory neuropathy 383

13. Diabetic foot syndrome

387

Judit Daróczy (†), György Jermendy, Erzsébet Révész Szabóné, Csaba Zsigmond Tóth

13.1. The concept of diabetic foot syndrome 387

13.2. Incidence, clinical significance 388

13.3. Pathomechanism 388

13.3.1. Neuropathy and angiopathy 389

13.3.2. Change in static conditions 390

13.3.3. Development of infection 390

13.4. Diagnostics 391

13.5. Therapy 392

13.6. Care, patient education, prevention 394

13.7. Management of diabetic foot ulcers based on international guidelines 395

13.7.1. Pathogenesis of chronic wound development 396

13.7.2. Need for hospital admission 397

13.7.3. Surgical treatment 397

13.8. Negative pressure therapy in the treatment of the diabetic foot 397

13.8.1. Parts of the system	398
13.8.2. Aspects of wound care	400
13.8.3. The biological effect of negative pressure therapy	401
13.8.4. Negative pressure therapy case reports	404
14. The relationship between diabetic neuropathy and depression	411
<i>Éva Kádár</i>	
14.1. Introduction	411
14.2. Available study results	411
14.3. Summary	413
15. Therapy for diabetic neuropathy	415
<i>Magdolna Békeffy, Viktor Horváth, György Jermendy, Péter Kempler, Gábor Pogátsa (†), László Rosta, Gábor Simonyi, Solomon Tesfaye, Tamás Várkonyi, Gábor Winkler</i>	
15.1. General aspects of the management of diabetic neuropathy	415
15.2. Pathogenesis-based disease-directed treatment	416
15.2.1. Aldose reductase inhibitors	416
15.2.2. Benfotiamine	418
15.2.3. Alpha-lipoic acid	436
15.2.4. Actovegin	455
15.2.5. Other biofactors in the treatment of diabetic neuropathy	455
15.3. Symptom-directed treatment	457
15.3.1. General aspects of symptom-directed treatment	457
15.3.2. Gabapentin	461
15.3.3. Pregabalin	462
15.3.4. Duloxetine	463
15.3.5. Tricyclic antidepressants	464
15.3.6. Other options for symptom-directed treatment	464
15.4. Combined treatment for diabetic neuropathy	466
15.4.1. The association between painless and painful neuropathy and cardiovascular complications—rationale for the combined disease- and symptom-directed management of neuropathy	466
15.4.2. Studies on the combined treatment of neuropathy	467
15.4.3. Combination of symptom-directed treatments—the COMBO-DN study	469
16. Neuropathy in chronic alcoholism and in alcoholic and non-alcoholic chronic liver diseases	485
<i>Katalin Keresztes, Ferenc Szalay</i>	
16.1. Pathomechanism of neuropathy in chronic liver diseases—common features of the pathomechanism of diabetic and hepatic neuropathies	485
16.2. Prevalence of neuropathy in chronic alcoholism and chronic liver disease of alcoholic origin	487

16.3. Prevalence of neuropathy in chronic liver diseases of non-alcoholic origin	489
16.4. Clinical signs of neuropathy in chronic liver disease	493
16.5. Therapy of neuropathy in chronic alcoholism and alcoholic and non-alcoholic chronic liver diseases	494
16.6. Benfotiamine and alpha-lipoic acid in the treatment of hepatic neuropathies	497

17. Role of cardiovascular autonomic neuropathy in the development of diabetic cardiomyopathy **505**

Viktor Horváth

18. Hypertension and neuropathy **509**

György Ábrahám, Imola Fejes, Ildikó Istenes, Péter Légrády

18.1. Introduction	509
18.2. Hypertension and diabetes	509
18.3. Hypertension and neuropathy	510
18.3.1. Hypertension and cardiovascular autonomic neuropathy	510
18.3.2. Neuropathy in hypertensive diabetics	512
18.3.3. Hypertension and peripheral sensory neuropathy	513
18.3.4. Hypertension and baroreflex sensitivity	514
18.4. Summary	515

19. Neuropathy in chronic kidney disease **519**

Gergő Attila Molnár, Eszter Sélley, István Wittmann

19.1. Introduction	519
19.2. Prevalence	519
19.3. Types and pathogenesis	520
19.3.1. Uraemic polyneuropathy	520
19.3.2. Mononeuropathy, i.e. multiple mononeuropathy	521
19.3.3. Specific forms that occur alongside kidney disease but are not directly caused by it	522
19.4. Clinical signs	522
19.5. Diagnosis	523
19.6. Differential diagnosis	524
19.7. Therapy	526
19.7.1. Disease-directed treatment	526
19.7.2. Symptom-directed treatment of polyneuropathy	527
19.7.3. Treatment of ischaemic mononeuropathy	527
19.7.4. Treatment of compression syndromes	527
19.8. Specific presentations and clinical syndromes	527
19.8.1. Limb ulcers in patients with kidney disease	527
19.8.2. Uraemic pruritus	529

20. Neuropathy in haematological diseases 533

Judit Demeter, Ildikó Istenes

20.1. Pernicious anaemia	534
20.2. Acute leukaemia	534
20.3. Hypereosinophilia syndrome (HES)	535
20.4. Diseases associated with monoclonal immunoglobulin production	535
20.4.1. Monoclonal gammopathy of undetermined significance (MGUS)	536
20.4.2. Multiple myeloma	537
20.4.3. Waldenström macroglobulinaemia	540
20.4.4. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes)	541

21. Critical illness polyneuropathy and myopathy 545

László Rosta

22. Drug-induced neuropathies 551

László Gerő, Ferenc Sztanek

22.1. Chemotherapeutic agents	551
22.2. Alkylating agents	552
22.3. Antimetabolites	552
22.4. Vinca alkaloids	552
22.5. Podophyllin derivatives	552
22.6. Monoclonal antibodies	552
22.7. Protein kinase inhibitors	553
22.8. Proteasome inhibitors	553
22.9. Taxanes and epothilones	553
22.10. Platinum compounds	554
22.11. Angiogenesis inhibitors	554
22.12. Neuropsychiatric agents	554
22.12.1. Topiramate	554
22.12.2. Phenytoin	555
22.12.3. Nitrous oxide	555
22.13. Antibiotics, antimicrobials	555
22.13.1. Isoniazid	555
22.13.2. Metronidazole	555
22.13.3. Chloroquine	555
22.13.4. Nitrofurantoin	555
22.13.5. Ciprofloxacin (and other floxacins, called girase inhibitors)	555
22.13.6. Colomycin	555
22.13.7. Amphotericin B	555
22.13.8. Antivirals	556
22.14. Neuropathies caused by vitamin deficiency	556
22.14.1. Niacin deficiency	556
22.14.2. Pyridoxine deficiency	556

22.14.3. Folic acid deficiency	556
22.14.4. Vitamin B ₁₂ deficiency	556
22.15. Insulin-induced "neuritis" (or treatment-induced neuropathy)	557
22.16. Statin treatment and neuropathy	558

23. Central manifestations of neuropathy	563
---	------------

Dinesh Selvarajah, Solomon Tesfaye, Tamás Várkonyi

23.1. Examination of auditory evoked potentials	563
23.2. Examination of visually evoked potentials	564
23.3. Central nervous system abnormalities in painful neuropathy	565
23.3.1. CNS changes in response to peripheral nerve injury and how these changes result in chronic pain in diabetes	565
23.3.2. Changes in the spinal cord	565
23.3.3. Changes in the brain—structural and functional	566
23.3.4. Recent studies	567
23.3.5. Clinical implications	568
23.3.6. Conclusions	568

24. Screening, diagnosis, and management of sensorimotor polyneuropathy in diabetes mellitus: an international expert consensus statement	573
--	------------

Péter Kempler

Index	577
--------------	------------